ES2358505T3 - Métodos para analizar isómeros de disulfuro de anticuerpos. - Google Patents

Métodos para analizar isómeros de disulfuro de anticuerpos. Download PDF

Info

Publication number
ES2358505T3
ES2358505T3 ES03745158T ES03745158T ES2358505T3 ES 2358505 T3 ES2358505 T3 ES 2358505T3 ES 03745158 T ES03745158 T ES 03745158T ES 03745158 T ES03745158 T ES 03745158T ES 2358505 T3 ES2358505 T3 ES 2358505T3
Authority
ES
Spain
Prior art keywords
protease
antibody
acetonitrile
digestion
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03745158T
Other languages
English (en)
Spanish (es)
Inventor
Ned M. Mozier
Robert L. Dufield
Jianming Mo
Gary S. Bild
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Application granted granted Critical
Publication of ES2358505T3 publication Critical patent/ES2358505T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
ES03745158T 2002-03-20 2003-03-20 Métodos para analizar isómeros de disulfuro de anticuerpos. Expired - Lifetime ES2358505T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36635002P 2002-03-20 2002-03-20
US366350P 2002-03-20

Publications (1)

Publication Number Publication Date
ES2358505T3 true ES2358505T3 (es) 2011-05-11

Family

ID=28454787

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03745158T Expired - Lifetime ES2358505T3 (es) 2002-03-20 2003-03-20 Métodos para analizar isómeros de disulfuro de anticuerpos.

Country Status (10)

Country Link
US (1) US20060171940A1 (enExample)
EP (1) EP1495056B1 (enExample)
JP (2) JP4441269B2 (enExample)
AT (1) ATE500273T1 (enExample)
AU (1) AU2003225900A1 (enExample)
DE (1) DE60336214D1 (enExample)
DK (1) DK1495056T3 (enExample)
ES (1) ES2358505T3 (enExample)
PT (1) PT1495056E (enExample)
WO (1) WO2003080674A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
EP2004231A4 (en) 2006-04-07 2013-07-10 Nektar Therapeutics CONJUGATES OF ANTI-TNF-ALPHA ANTIBODY
EP2451838A1 (en) * 2009-07-09 2012-05-16 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Stabilized immunoglobulin constant domains
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
CN119861168B (zh) * 2024-12-30 2025-09-23 浙江大学 一种识别β-内酰胺类抗生素中二聚物异构体的智能分析系统及方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849352A (en) * 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
JP4418745B2 (ja) * 2002-05-28 2010-02-24 ユセベ ファルマ ソシエテ アノニム 抗体ｐｅｇ位置異性体、それを含む組成物及びその使用

Also Published As

Publication number Publication date
WO2003080674A1 (en) 2003-10-02
AU2003225900A1 (en) 2003-10-08
PT1495056E (pt) 2011-03-29
JP5352761B2 (ja) 2013-11-27
JP2009153528A (ja) 2009-07-16
EP1495056A1 (en) 2005-01-12
JP2006505497A (ja) 2006-02-16
DE60336214D1 (de) 2011-04-14
EP1495056A4 (en) 2005-09-28
ATE500273T1 (de) 2011-03-15
EP1495056B1 (en) 2011-03-02
JP4441269B2 (ja) 2010-03-31
US20060171940A1 (en) 2006-08-03
DK1495056T3 (da) 2011-05-02

Similar Documents

Publication Publication Date Title
JP7146871B2 (ja) 血漿カリクレイン結合タンパク質
ES2288873T3 (es) Anticuerpos de activacion del factor ix/factor ixa.
ES2975006T3 (es) Anticuerpos humanos de alta afinidad contra el receptor humano de IL-4
ES2726040T3 (es) Antagonistas de PCSK9
ES2813432T3 (es) Proteínas y péptidos modificados
CN103635489B (zh) 血浆前激肽释放酶结合蛋白
ES2620684T3 (es) Agentes de unión a esclerostina
ES2517872T3 (es) Anticuerpos humanos de alta afinidad para el factor de crecimiento nervioso humano
ES2611286T3 (es) Régimen de dosis variables múltiples para el tratamiento de enfermedad de Crohn y colitis ulcerosa
ES2818074T3 (es) Agente de unión a IL-17A y sus usos
ES2765418T3 (es) Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
CN101743254A (zh) 结合par-2的抗原结合蛋白
CN117769434A (zh) 与C1s结合的抗体和其用途
CN111704672A (zh) 抗血浆激肽释放酶抗体
JP7017641B2 (ja) 抗ＴｒｋＡ抗体
US9587034B2 (en) Anti-mIgE antibodies that bind to the junction between CH4 and CεmX domains
JP5352761B2 (ja) 抗体ジスルフィド異性体、その使用及びその分析法
CN117980329A (zh) 用于预防或治疗自身免疫疾病的抗体药品
CN107406511A (zh) Pcsk9抗体、其抗原结合片段及其医药用途
US20260139047A1 (en) Pharmaceutical composition containing fusion protein
JP2006505497A5 (enExample)
KR20230159819A (ko) 골관절염, 류마티스 관절염, 관절 및 힘줄 장애를 치료하기위한 조성물 및 방법
BR112018013256B1 (pt) Anticorpo para pcsk9 ou fragmentos de ligação ao antígeno do mesmo, seus usos e composição farmacêutica
BR112016009948B1 (pt) Agente de ligação à il-17a, seus usos, vetor, e composição farmacêutica